drug as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.
Until now, Amarin was approved only for a much smaller niche indication – the lowering of triglycerides in patients who have extremely high levels of the blood fats. Some patients in the trial reported slightly higher risk of bleeding and a small increase in irregular heart rhythm, safety concerns that panel members suggested highlighting on the drug’s label.
In May, the FDA granted Amarin priority review for Vascepa in relation to a much wider group of patients who have less extreme levels of the dangerous blood fats. The company says it is a condition affecting millions of patients.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: thejournal_ie - 🏆 32. / 50 Read more »
Source: IrishMirror - 🏆 4. / 98 Read more »
Source: IrishMirror - 🏆 4. / 98 Read more »
Source: rtenews - 🏆 1. / 99 Read more »